Skip to main content
Lisinopril Tablets IP 5 mg Manufacturer

Lisinopril Tablets IP 5 mg Manufacturer in India – Healthy Life Pharma Pvt. Ltd.

Lisinopril Tablets IP 5 mg Manufacturer product packaging

Lisinopril Tablets IP 5 mg | Manufacturer

Product image for Lisinopril Tablets IP 5 mg Manufacturer; contract manufacturing, oem & quality control.

Product Information

Generic NameLisinopril
ManufacturerHealthy Life Pharma Pvt. Ltd.
HSN Code30049071
PharmacopoeiaIP
Product TypeTablet
CategoryAntihypertensive drugs – ACE Inhibitor
SubcategoryACE Inhibitor
Active IngredientLisinopril
Strength5 mg
Dosage FormTablet
Pack Size10 x 10 Tablets / Box (Alu-Alu / Blister)
Route of AdministrationOral
Prescription RequiredYes
Therapeutic CategoryAntihypertensive drugs – ACE Inhibitor

Medicine Details & Safety

Short DescriptionHealthy Life Pharma invites contract and third-party manufacturing enquiries for Lisinopril Tablets IP 5 mg from pharmaceutical marketing companies, institutional buyers and brand owners. Production specifications, batch size and packaging are agreed against the approved product dossier and purchase requirements.
Approved Uses / Indications1. First-line management of mild, moderate, and severe essential hypertension. 2. Adjunctive treatment in chronic stable angina pectoris and reduction of cardiovascular mortality.
Full Description

Healthy Life Pharma invites contract and third-party manufacturing enquiries for Lisinopril Tablets IP 5 mg from pharmaceutical marketing companies, institutional buyers and brand owners. Production specifications, batch size and packaging are agreed against the approved product dossier and purchase requirements.

Product technical specifications

Generic nameLisinopril
CompositionLisinopril
Strength5 mg
CategoryAntihypertensive drugs – ACE Inhibitor
PharmacopoeiaIP
Dosage formTablet

Product technical specifications

Generic nameAcarbose
CompositionAcarbose
Strength25 mg
CategoryAntidiabetic Drugs
PharmacopoeiaUSP / IP
Dosage formTablet

Manufacturing capabilities and infrastructure

For Lisinopril Tablets IP 5 mg, assess the approved formulation process, equipment suitability, batch scale and in-process controls for the Tablet presentation. Confirm environmental requirements and validated process before production.

Quality control and assurance

Request the approved finished-product specification for Lisinopril Tablets IP 5 mg, including applicable identity, assay, uniformity and performance tests for the Tablet presentation. Confirm analytical methods, acceptance criteria and batch release documentation, including COA availability.

Primary and secondary packaging

The catalogue pack for Lisinopril Tablets IP 5 mg is 10 x 10 Tablets / Box (Alu-Alu / Blister). Confirm primary packaging compatibility, stability evidence, artwork, batch coding and leaflet requirements against the approved specification.

Contract manufacturing and private label

Submit the target market, strength, pharmacopoeial specification, forecast volume and brand artwork. Agree feasibility, batch size, quality agreement, production schedule and release criteria before execution.
Dosage InstructionsAdminister orally once or twice daily at the same time each day, with or without food. Do not discontinue abruptly; gradual downward titration is recommended under medical supervision.
Side EffectsCommon: Peripheral edema (ankle swelling), dizziness, headache, flushing, fatigue. Uncommon: Postural hypotension, palpitations, dyspepsia, dry cough, muscle cramps. Rare: Bradycardia, severe hypotension, syncope, hyperkalemia, angioedema.
Warnings and PrecautionsHypotension Monitoring: Monitor seated blood pressure during initial titration. Electrolyte Balance: Periodically verify serum potassium and renal clearance in patients with underlying renal insufficiency. Heart Failure Caution: Use with careful clinical assessment in heart failure patients.
Contraindications1. Hypersensitivity to Lisinopril or related cardiovascular agent classes.
2. Severe cardiogenic shock, second- or third-degree atrioventricular block without a pacemaker.
3. Clinically severe hypotension (systolic BP < 90 mmHg).
4. Pregnancy and lactation (for ACE inhibitors and ARBs).
Drug Interactions1. Other Antihypertensives & Diuretics: Additive blood-pressure-lowering effects requiring monitored dose titration.
2. Potassium Supplements & Potassium-Sparing Diuretics: Elevated risk of hyperkalemia (with RAAS blockers).
3. NSAIDs: May diminish antihypertensive response and increase risk of acute renal dysfunction.

Frequently Asked Questions

QuestionAnswer
Can I request third-party manufacturing for Lisinopril Tablets IP 5 mg?Submit your brand, quantity and packaging requirements for manufacturing feasibility review.
Which pharmacopoeial standard applies for Lisinopril Tablets IP 5 mg?The source specification is IP; confirm the required standard before contracting.
What quality tests are applicable for Lisinopril Tablets IP 5 mg?Request the approved finished-product specification and batch testing plan.
Can packaging be customized for Lisinopril Tablets IP 5 mg?Submit artwork and pack requirements for technical and regulatory review.
How do I request a manufacturing quotation for Lisinopril Tablets IP 5 mg?Provide forecast volume, target market, strength and packaging requirements.

Product Hashtags

#Lisinopril#Manufacturer#PharmaB2B

Related Products

Latest Posts